



## AGENDA

### GENERAL HOSPITAL AND PERSONAL USE DEVICES PANEL

#### Medical Device Supply Chain Resiliency and Shortages & Proposed 506J Device List

February 6, 2024

**Panel Chairperson**

William R. Jarvis, MD

**Designated Federal Officer**

Jarrold Collier, MS

- 9:00 AM**      **Call to Order**  
**Panel Introductions**  
**Conflict of Interest Statements**
- 9:20 AM**      **Opening Remarks**  
Suzanne Schwartz, MD, MBA  
*Director, Office of Strategic Partnerships and Technology Innovation*
- 9:30 AM**      **FDA Presentation and Questions for FDA**  
Tammy Beckham, DVM, PhD  
*Associate Director, Resilient Supply Chain Program*
- 10:15 AM**      **Break**
- 10:30 AM**      **Stakeholder Presentation: Medical Device Manufacturers**  
Mark B. Leahey  
*President and CEO, Medical Device Manufacturers Association (MDMA)*
- Abby Pratt  
*Senior Vice President, Global Strategy and Analysis*  
*Advanced Medical Technology Association (AdvaMed)*
- 10:45 AM**      **Stakeholder Presentation: Healthcare Systems**  
Paul D. Biddinger, MD, FACEP  
*Chief Preparedness and Continuity Officer, Mass General Brigham*  
*Ann L. Prestipino, MPH Endowed Chair in Emergency Preparedness*  
*Director, Center for Disaster Medicine, Massachusetts General Hospital Department of*  
*Emergency Medicine*  
*Director, Harvard T.H. Chan School of Public Health Emergency Preparedness*  
*Research, Evaluation and Practice (EPREP) Program*
- 11:00 AM**      **Stakeholder Presentation: Healthcare Providers**  
Jacob F. Collen, MD, FACP, FCCP, FAASM, COL, MC, USA  
*Pulmonary, Critical Care and Sleep Medicine*  
*Professor of Medicine, Uniformed Services University*

*Internal/Confidential/Deliberative*



<b>11:15 AM</b>	<b>Questions to Stakeholders</b>
<b>11:30 AM</b>	<b>Open Public Hearing*</b>
<b>12:30 PM</b>	<b>Lunch</b>
<b>1:10 PM</b>	<b>Working Session 1 – FDA Questions to the Panel</b>
<b>2:30 PM</b>	<b>Break</b>
<b>2:45 PM</b>	<b>Working Session 2 – FDA Questions to the Panel</b>
<b>3:30 PM</b>	<b>Panel Deliberations</b>
<b>4:30 PM</b>	<b>FDA Summations</b>
<b>5:00 PM</b>	<b>Adjournment</b>

\* Open Public Hearing – Interested persons may present data, information, or views, orally or in writing, on the issue pending before the panel. Scheduled speakers who have requested time to address the panel will speak at this time. After they have spoken, the Chair may ask them to remain if the panel wishes to question them. The Chair will then recognize unscheduled speakers as time allows. Only the panel may question speakers during the open public hearing.